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Background: Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the 
T-cell immune response against tumor cells. Ipilimumab is a monoclonal antibody directed 
against CTLA-4.
Objective: This review describes the basic mechanism of ipilimumab and discusses data avail-
able to date with regards to its safety and efficacy profile.
Methods: Data from clinical trials including abstracts was reviewed using the PubMed Database, 
as well as the American Society of Clinical Oncology Abstract Database.
Conclusion: CTLA-4 inhibition with a monoclonal antibody is usually well tolerated and 
has efficacy as a therapeutic agent in a variety of cancers. The classical response interpreta-
tion has changed because of the delayed mechanism of action. The toxicities are autoimmune 
events and guidelines for treatment of these effects are discussed. Therapy with ipilimumab 
leads to durable responses. The first two Phase III randomized studies showed an improvement 
of   survival at 1, 2, and 3 years. Other studies are currently underway to better understand the 
optimal treatment administration of ipilimumab in melanoma.
Keywords: melanoma, CTLA-4, ipilimumab, immune-related adverse events, melanoma, 
modified immune response criteria
Introduction
The 1-year survival of patients with metastatic melanoma is 25%, with a median 
  survival of around 7–9 months.1–3 Chemotherapy has been widely used to treat 
patients with unresectable disease, but most of the time the disease fails to respond.4 
Non-specific immunotherapy has induced durable responses in very few patients. 
The Food and Drug Administration approved therapies for metastatic melanoma are 
dacarbazine and interleukin 2 (IL-2), and more recently, ipilimumab (March 2011) 
and vemurafenib (September 2011).
The rationale for studying immunotherapies is based on evidence of   spontaneous 
remissions and observed response to biological agents that stimulate the immune   system. 
Cytotoxic T lymphocyte antigen 4 (CTLA-4) exerts an inhibitory control on T-cell 
  activation. Therefore, blockade of CTLA-4 is a unique way of enhancing patients’ 
immune response against tumors. Ipilimumab is a humanized monoclonal antibody 
against CTLA-4, recently approved for the treatment of metastatic melanoma. This review 
concentrates on the recent development of melanoma treatments with ipilimumab.
Mechanism of action of ipilimumab
CTLA-4 is important in immune homeostasis and in the induction of tolerance to 
  self-antigens.5,6 T-cell activation requires at least two signals: the presentation of an 
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antigen to the T-cell receptor by a major histocompatibility 
complex molecule on an antigen presenting cell, and interac-
tion of the T-cell with other receptors that either enhance or 
inhibit the T-cell response.7 CD28 and CTLA-4 competitively 
interact with the B7-1 and B7-2 ligands located on the antigen 
presenting cell, with antagonistic effects.8,9 CD28 enhances 
T-cell activation and IL-2 production and CTLA-4 antago-
nizes T-cell activation by interfering with IL-2 secretion and 
IL-2 receptor expression.10 IL-2 stimulates T-cell growth, 
but has also been implicated in the expansion of regulatory 
T-cells that express CTLA-4. CTLA-4 binds to B7-1 and B7-2 
ligands with greater affinity than CD28.11 Although CD28 is 
constitutively expressed on naive T-cells, CTLA-4 becomes 
functional only after T-cell activation.12 This temporal delay 
in CTLA-4 upregulation allows for initial T-cell activation 
by CD28, followed by a regulatory feedback loop mediated 
by CTLA-4. Ipilimumab binds to CTLA-4 and allows the 
T-cell immune response to persist (Figure 1).
Preclinical data
In cynomolgus macaques, administration of a CTLA-4 
antibody resulted in enhanced antibody responses to 
hepatitis surface antigen and a human melanoma cell 
vaccine.13 The injection of anti-CTLA-4 antibodies in 
mouse models stimulates the rejection of murine tumors 
such as colon, ovarian, and fibrosarcoma models, but can 
also lead to lymphoproliferative disease and autoimmunity 
in other organs. The effects of these antibodies can be 
potentiated by   chemotherapy. CTLA-4 knockout mice 
develop fatal autoimmunity resulting from unopposed T-cell 
activation and reaction to self-antigens.14
Pharmacodynamics and immunity 
stimulation
There are two mechanisms by which CTLA-4 blockade 
can create anti-tumor responses.15 The first mechanism is 
by interfering with tumor-specific effector cells such as 
CD8 cells where CTLA-4 blockade causes increased clonal 
expansion.16,17 Studies using flow cytometry to compare cell 
surface marker expression on peripheral blood mononuclear 
cells before and after treatment with ipilimumab, in combi-
nation with interleukin-2 therapy, showed that HLA-DR, 
a marker of T-cell activation, increased after treatment 
on CD3+CD4+ and CD3+CD4- (likely CD8+) cells.18 
The second mechanism is via depletion of tumor-induced 
CD4+CD25+ regulatory T-cell (Tregs), which inhibit 
immune response to tumor-associated antigens. Tregs are 
a suppressive CD4 T-cell population that expresses CD25 
(the high affinity IL-2α receptor subunit). Tregs also produce 
immunosuppressive cytokines such as IL-10.19 Additionally, 
an increase in T helper 17 (Th17) cells, a distinct lineage 
of CD4+ T-cells producing specific cytokines (IL-17 and 
IL-22),20 was associated with fewer relapses in a Phase II 
study of 75 patients treated with ipilimumab (3 or 10 mg/kg) 
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Figure 1 when an antigen (Ag) is presented in the context of the major histocompatibility complex (MHC) to the T cell receptor (TCR), binding of B7 with CD28 occurs 
which activates the T cell. Slightly later, the activated T cell stimulates CTLA4 which also binds to B7 to down-regulate the T cell. ipilimumab inactivates the binding of CTLA4 
with B7, allowing the T cell to remain activated. 
Abbreviations: Ag, antigen; MHC, major histocompatibility complex; TCR, T cell receptor.
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alone or in combination with melanoma-specific peptides.21 
However, IL17 secretion is also linked to the development 
of colitis (see below).
Melanoma-specific tumor antigens have been studied in 
the context of ipilimumab treatment. Ipilimumab enhances 
immunity to NY-ESO-1, a cancer/testis antigen expressed 
in a subset of patients with melanoma. In 140 ipilimumab-
treated patients, 16% were seropositive at baseline and 
22% following treatment. These NY-ESO-1-seropositive 
patients are more responsive to ipilimumab than NY-ESO-1-
seronegative patients. Furthermore, NY-ESO-1-seropositive 
patients with associated CD8(+) T-cells experienced greater 
clinical benefit (77%) than those with undetectable CD8(+) 
T-cell response (14%).22 Inducible costimulator (ICOS), 
a member of the immunoglobulin gene family, is expressed 
on CD4+ and CD8+ T-cells following activation. ICOS 
functions as a costimulatory molecule on activated T-cells 
and increases effector T-cell survival.23 An increase in the 
frequency of CD4+ ICOS-high cells is seen in patients treated 
with ipilimumab, compared to untreated melanoma patients 
or healthy volunteers. This increase may be associated with 
a clinical benefit at week 24 and an increased survival.24 
Another antigens associated to melanocyte differentiation, 
the melanoma inhibitor of apoptosis protein (ML-IAP or 
livin) is overexpressed in melanoma and contributes to dis-
ease progression and to treatment resistance. CD4(+) and 
CD8(+) cellular responses have been observed against livin 
and are associated with novel class I and class II epitopes. 
Some patients treated with ipilimumab develop humoral 
immune responses to livin, which seems associated with 
clinical benefit.25
There is no early predictive marker of tumor response 
identified in clinical studies of CTLA-4 inhibition. Various 
studies are searching for pharmacodynamic biomarkers. 
In 35 patients treated with ipilimumab (10 mg/kg every 
3 weeks for four doses with maintenance therapy as clinically 
indicated), lymphocyte counts and flow cytometry for CD8/
CD4/CD25+ populations showed increases in the absolute 
lymphocytic count related to an increase of CD8+ T-cells 
between weeks 1 and 7. There was a statistically significant 
increase in CD8+ T-cells in responding patients, but not 
in CD4+ T-cells. Changes in CD4+/CD25+ T-cells did not 
correlate with clinical response.26 However, in a study of 
patients with advanced localized melanoma (stage IIIB–C) 
treated with neoadjuvant ipilimumab (10 mg/kg every 3 weeks 
for two doses preoperatively and for two doses postoperatively, 
a significant increase in the frequency of circulating Treg cells 
was observed from baseline to 6 weeks.27 These nonaligned 
observations require more study to really understand the 
modulation of the immune system in this patient population.28 
Furthermore, most clinical responses occur after 12 weeks of 
treatment, and it is possible that the immune system has not 
fully mounted proper anti-melanoma activity in the first few 
weeks following ipilimumab administration. However, to avoid 
a costly treatment that would not help a patient, predictive 
markers of response should ideally be identified.
There are no specific clinical predictors of response 
either. The variable most closely related is the presence of 
autoimmune toxicities. In 50 patients who had a grade 3 or 
4 autoimmune toxicity, 28% achieved an objective response 
(P = 0.0004). Some autoimmune events required treatment 
with steroids. In 23 patients who responded to CTLA-4 anti-
bodies and received steroids for adverse effects, the covariate 
analysis revealed that administration of steroids had no effect 
on the duration of response (P = 0.23).29 Disease burden, as 
diagnosed by elevated LDH and/or brain metastases, does 
not correlate with an absence of response. There was no 
association between baseline LDH levels and disease control 
in previously treated patients with M1c-stage melanoma, 
who received ipilimumab (10 mg/kg every 3 weeks). Of 
123 patients with M1c-stage disease, 81 had elevated LDH. 
Seventeen (21.0%) experienced disease control, compared 
to 28.6% of patients with normal LDH levels. Ipilimumab 
appears to induce clinical benefit even in patients with M1c-
stage melanoma and elevated LDH levels.30 The compas-
sionate expanded access program was initially an open-label 
study of ipilimumab 10 mg/kg every 3 weeks for four doses 
(CA184-045). There were 165 asymptomatic patients with 
stable brain metastases at baseline who were enrolled at this 
dose. The overall survival of this patient population at 1 year 
was 20%. This compared to a controlled study of patients with 
stable brain metastases, who had a 1-year survival of 31% 
(CA184-042).31 Thus, it appears that ipilimumab is active in 
some patients at any stage of the disease and it is not possible 
to determine upfront who will respond and who will not.
Pharmacokinetics and metabolism
After a single dose of ipilimumab, the plasma concentration 
decay over time could be monoexponential (four subjects) 
or bioexponential (ten subjects).32 Tmax occurred at the end of 
the ipilimumab infusion in all subjects. The mean Cmax was 
155.94 ± 64.5 µg/mL. The mean terminal elimination half-life 
was 299.4 ± 126.9 hours or 12.5 days, consistent with antibody 
pharmacokinetics, such that a single dose would give levels of 
over 10 µg/mL for at least 60 days. The mean   apparent volume 
of distribution at steady state was 4.07 ± 1.3 L. The mean total 
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body clearance was 0.01 ± 0.004 L/hour. In another study of 
ipilimumab (3 mg/kg), the mean peak concentration after 
the first dose was 72 ± 33 µg/mL, and the trough before the 
second dose was 12 ± 7 µg/mL. After therapy was completed, 
the mean plasma concentration was 99 ± 41 µg/mL, with a 
trough of 17 ± 10 µg/mL after 3 weeks. There was no correla-
tion between plasma concentrations or clearance and tumor 
responses or toxicity. In addition, clearance increases with 
body weight, but as expected for a monoclonal antibody, is not 
affected by renal or hepatic functions,33 or by steroid use.34
Clinical efficacy
The first randomized study to show a benefit of ipilimumab 
treatment in patients previously treated for metastatic 
melanoma tested the monoclonal antibody (3 mg/kg every 
3 weeks for four doses) with or without a glycoprotein 100 
(gp100) peptide vaccine. The control was gp100 alone. All 
patients were HLA-A*0201–positive and had unresectable 
stage III or IV melanoma progressing after therapy for meta-
static disease. Patients were randomly assigned to receive 
ipilimumab plus gp100 (403 patients), ipilimumab alone 
(137 patients), or gp100 alone (136 patients).35 The primary 
end point was overall survival. The median overall survival 
was 10 months among patients receiving ipilimumab com-
pared to 6.4 months among patients receiving gp100 alone. 
This study led to the Food and Drug Administration approval 
of ipilimumab. The second randomized study compared 
dacarbazine (850 mg/m2) plus ipilimumab (10 mg/kg every 
3 weeks for four doses) or placebo, followed by dacarbazine 
alone every 3 weeks through to week 22.36 Patients with 
clinical benefit received ipilimumab or placebo every 
12 weeks as maintenance therapy. The primary end point 
was overall survival. The median overall survival was 
11.2 months among patients receiving ipilimumab compared 
to 9.1 months among patients receiving dacarbazine alone. 
However, because of the immune mechanism of action, 
long-term survival rates are observed; at 1 year, it was 
47.3% versus 36.3%; at 2 years, 28.5% versus 17.9%; and 
at 3 years, 20.8% versus 12.2%.
Other studies are testing various combinations. A study of 
36 patients treated with ipilimumab and IL-2 demonstrated 
an objective response rate of 22%.18 Twenty-seven patients 
were treated with ipilimumab (10 mg/kg on day 1) and oral 
temozolomide (200 mg/m2 on days 1–4) every 3 weeks for 
four courses, followed by   maintenance. By immune-related 
response criteria (see below), there were six (22%) confirmed 
partial responses and twelve (44%) patients experienced 
stable disease for an overall   disease control rate of 67%.37 
In a Phase I study of ipilimumab (fixed dose of 10 mg/kg) 
and bevacizumab (starting dose of 7.5 mg/kg), the overall 
response rate was 38% for partial responses, with stable dis-
ease seen in 28%. All responses lasted longer than 6 months. 
Post-treatment biopsies showed activated vessel endothelium 
with extensive T-cell trafficking and marked increase in CD4/
CCR7/CD45RO central memory cells in the peripheral blood 
of most patients, not seen with ipilimumab alone.38
An international randomized double-blind study of 
adjuvant ipilimumab versus placebo has recently completed 
accruals. The study has not yet matured and results will be 
reported in the next few years (CA184-029).
New insights for response evaluation
The modification of native immune processes by ipilimumab 
extends observation of benefits weeks to months after treat-
ment administration. Hence, classical chemotherapy response 
criteria do not measure appropriately the immunotherapeutic 
effects. An initial increase in tumor burden or the appearance 
of new lesions could precede immunotherapy-induced tumor 
regression. Novel criteria for the evaluation of antitumor 
responses with immunotherapeutic agents have been pro-
posed after a detailed analysis of the Phase II clinical trial 
program with ipilimumab. Ipilimumab monotherapy results 
in four distinct response patterns: (1) shrinkage in baseline 
lesions, without new lesions; (2) durable stable disease 
(in some patients followed by a slow, steady decline in total 
tumor burden over a period of months); (3) response after an 
increase in total tumor burden; and (4) response in the presence 
of new lesions. All patterns could be associated with favorable 
survival. Response patterns (1) and (2) may be captured using 
standard methods, but response patterns (3) and (4) would be 
classified as progressive disease using Response Evaluation 
Criteria in Solid Tumors or the World Health Organization 
criteria. Because patients on ipilimumab may have delayed 
responses or durable stable disease even after apparent disease 
progression, these new immune-related response criteria are 
now evaluated to capture additional response patterns observed 
with immune therapy in advanced melanoma beyond those 
described by conventional assessments.39,40 Examples of radio-
logic immune-related response criteria and toxicity in patients 
with advanced melanoma treated with ipilimumab can be seen 
in the pictorial assay published by O’Regan et al.41
Safety and tolerability
Characteristic side effects from inhibition of CTLA-4 are called 
immune (or inflammation)-related adverse events (IRAEs). 
A retrospective review of 14 completed Phase I–III trials 
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of ipilimumab in patients with advanced melanoma looked 
at safety data pooled from 1498 patients. IRAEs occur in 
64.2% and result in death in ,1% of patients. Most com-
mon IRAEs are skin rash, hepatitis, colitis, endocrinopathies, 
particularly hypopituitarism, and hepatic inflammation 
or neurological impairment. Other organ affections are 
seen in ,1% of patients and include uveitis, pneumonitis, 
  pancreatitis, autoimmune nephritis, myasthenia gravis, and 
others. Most IRAEs occurred during induction (initial four 
doses given once every 3 weeks).42 There is an association 
with the development of IRAEs and tumor regression in 
patients with metastatic melanoma or renal cell carcinoma, 
as well as a prolonged time to relapse in those with resected 
high-risk melanoma, similar to other data.43 The timing of 
IRAEs is variable and might depend on peak dosing and 
area under the curve of the drug. IRAEs may occur after the 
first cycle and may require aggressive, prompt management 
with   corticosteroids. Treating the adverse autoimmune effects 
with corticosteroids does not affect anti-tumor activity.29
Rash
This is by far the most common side effect of ipilimumab. 
The rash can be very itchy and is treated first with emollient 
skin lotion, anti-histamine, or in difficult cases, local steroid 
application.
Colitis
The occurrence of autoimmune enterocolitis is about 20%, 
with adverse events graded 3 and 4.44 There is a 5% mortality 
rate in patients who developed autoimmune colitis and a sig-
nificant risk for colonic perforation if untreated. Complaints 
include watery stools, abdominal pain, fever, nausea and 
vomiting, and anal pain. Colon biopsies show neutrophilic 
and/or lymphocytic infiltrates and even granulomas. When 
serum IL-17 levels were measured in patients treated with 
ipilimumab (10 mg/kg), comparing patients who developed 
colitis to those without IRAEs, significantly higher serum 
IL-17 levels were observed in patients with colitis (n = 13) 
versus patients with no IRAEs (n = 16). Serum IL-17 levels 
showed no difference at baseline, but in patients with colitis 
paralleled the course of the inflammation.45 Diarrhea usually 
responds to treatment by restriction of oral intake and steroid 
use. When enterocolitis is refractory to high-dose steroids, 
the treatment should add a dose of infliximab. Guidelines 
for the treatment of diarrhea have been developed and 
validated based on the above clinical experience.46 Safety 
data from studies conducted by Medarex (which were 
generally conducted before the implementation of diarrhea 
  guidelines) were compared with those of Bristol Meyers 
Squibb   (conducted after the guideline implementation). The 
dose of ipilimumab in the Medarex studies was generally 
3 mg/kg, while that of the subsequent studies was 10 mg/kg 
every 3 weeks for four doses. There was a 50% reduction in 
gastrointestinal perforation or colectomy rate after guideline 
implementation, despite the higher dose of ipilimumab.46
Prophylactic budesonide does not provide clinical 
  benefit.47 Patients with metastatic melanoma given ipili-
mumab 10 mg/kg every 3 weeks for four doses also received 
Table 1 Treatment outcome with diarrhea
Grade Length of diarrhea % episodes (from  
5 studies)
Treatment Outcome
1 #5 days 46% Symptomatically without immunosuppressive agents 87% resolution
1 .5 days 18% Symptomatically with immunosuppressive agents 67% resolution
2 ,3 days 12% Symptomatically Majority resolved
2 .3 days 10% Symptomatically with immunosuppressive agents Majority resolved
$3 Any 13% Symptomatically with immunosuppressive agents .90% resolution within  
2 weeks (median 1 week)
Table 2 immunosuppressive guidelines
Grade Description Treatment Outcome
1 Less than 4 stools/day Start loperamide, 1 pill after each liquid stool 
Drink gatorade
Does not resolve after 48 hours,   
call clinic
2 Between 4–6 stools/day Start loperamide, 1 pill after each liquid stool 
Drink gatorade
Does not resolve after 48 hours,   
call clinic
3 7 or more stools/day 
Up and going normally
Start budesonide 1 pill/day and loperamide, 1 pill after each liquid stool 
Drink gatorade
Does not resolve after 24 hours,   
call clinic
7 or more stools/day 
Bedridden or weak
Take Budesonide 1 pill, and either go to clinic or ER and tell the ER  
doctor to call the oncology attending immediately
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Table 3 Doses of immunosuppressive agents
Drug Dose Outcome
Budesonide 3 mg/day If no benefit after  
48 hours go to  
intravenous prednisone 
Order a colonoscopy 
to diagnose the colitis
Prednisone Start with intravenous  
methylprednisolone 125 mg  
twice a day down to 60 mg  
daily within 1 week, then  
administer a 30 day tapering  
course of prednisone starting  
at 60 mg by mouth daily
if worsening go to 
aflibercept
Aflibercept 5 mg/kg intravenously
prophylactic budesonide or placebo. Of the 115 patients 
treated with placebo or budesonide, the rate of grade 2 or 
higher diarrhea was 35.0% and 32.7%, the best overall 
response rate 15.8% and 12.1% and the median overall sur-
vival 17.7 and 19.3 months, respectively. Again, the disease 
control rate was higher in patients with grade 3 to 4 IRAEs 
than in patients with grade 0 to 2 IRAEs, although some 
patients with grade 1 to 2 IRAEs also experienced clinical 
benefit. Budesonide should not be used prophylactically to 
prevent colitis-induced ipilimumab therapy.
Guidelines for the management of colitis
Guidelines were developed on the basis of 687 episodes of 
diarrhea or colitis in 511 subjects enrolled in five studies of 
ipilimumab (3 or 10 mg/kg every 3 weeks for four doses). 
Rapid institution of steroid therapy (within 5 days) leads to 
faster resolution of symptoms (see Tables 1–3).46
Hypophysitis
A review of patients who developed autoimmune hypophysitis 
after treatment with ipilimumab showed that eight of the 
nine patients had correlative increase in pituitary size on 
  imaging.48 These patients all had symptoms and laboratory 
findings consistent with this diagnosis. A sudden headache 
could be the herald of pituitary involvement and should 
trigger consideration of this IRAE.49 Therefore, patients 
should be monitored with baseline TSH; other laboratory 
investigations such as cortisol, thyroxine, testosterone or 
LH/FSH levels should be monitored to rule out a suspicion 
of hypophysitis. A short course of high-dose steroids may 
improve pituitary function. Patients with evidence of autoim-
mune hypophysitis should stop ipilimumab and be treated 
with physiological hormone replacements with hydrocorti-
sone and thyroxine, with or without sexual hormones.
Conclusions
The discovery of cytotoxic T-lymphocyte antigen-4 
(CTLA-4) and its role as a key negative regulator for T-cells 
have led to the approval of ipilimumab as a new approach to 
treat unresectable melanoma. Ipilimumab inhibits CTLA-4 
and prolongs immune response. Consequently, antitumor 
response has been associated with a higher incidence 
of autoimmunity reactions, which can be severe but are 
commonly manageable with steroids. There is currently 
no evidence that the use of steroids reduces the response 
mechanism fueled by ipilimumab. Ipilimumab yields 
prolonged antitumor effects in 20%–30% of patients with 
melanoma; however, the effect of this immunotherapy takes 
many weeks to peak. This delay response time has engen-
dered a new definition of response criteria for immuno-
therapy, because the classical Response Evaluation Criteria 
in Solid Tumors criteria are inadequate to measure efficacy. 
Responses can occur later and may be more durable with 
ipilimumab than with traditional chemotherapy. The current 
12-week benchmark may not be long enough to determine 
response to ipilimumab and patients should be observed 
  longer. The immune response generated in the first few 
weeks of therapy, may be wrongly interpreted as progressive 
disease on radiological imaging. In this instance, the T-cell 
infiltration and inflammation cause the increased tumor 
size on radiological images. The appearance of new lesions 
may also be related to immune-mediated inflammation in 
previous areas of subclinical micro-metastases. Observing 
patients for 20 weeks after the first dose of ipilimumab 
before making the decision to modify therapy, as long as 
the cancer is not life threatening, might be   worthwhile. The 
current approved dose is 3 mg/kg every 3 weeks for four 
doses. Maintenance treatment is not approved, but patients 
who are progressing after an initial clinical benefit may be 
retreated if clinically indicated. Studies of higher dosing 
(10 mg/kg) are underway. An individualized approach with 
a predictive marker of early response would be crucial, 
especially since many patients have delayed responses. 
Increases in the absolute lymphocyte count may be a crude 
marker of immune stimulation.50 Apparition of autoimmune 
reactions may be an early sign of effectiveness.   Monitoring 
immunologic changes to better understand the role of ipili-
mumab has not been established. Ipilimumab is also under 
investigation in combination with other agents, and in a 
smaller cohort of patients with various cancers.
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